Henry J. Riordan, PhD
Chief Development Officer
Henry J. Riordan, PhD, Chief Development Officer, was one of the original team members at Worldwide Clinical Trials. A prolific author of more than 120 peer-reviewed abstracts, articles, chapters, and books, Dr. Riordan has advanced training and expertise in quantitative methods, biostatistics, experimental design, neurophysiology, neuroimaging, and clinical neuropsychology. Earlier in his career, he was responsible for helping to establish Worldwide’s specialized early phase patient study unit. Dr. Riordan currently oversees the CNS, General Medicine, Cardiometabolic, and Oncology Franchises.
ABOUT HENRY J. RIORDAN, PhD
Dr. Riordan brings together Worldwide’s scientific assets across the CNS, general medicine, cardiometabolic, and oncology divisions and connecting the critical functions that serve to differentiate Worldwide by implementing strategies and tactics consistent with the company’s vision of being the leader in the application of rigorous methodology and medically/scientifically advanced drug development processes producing reliable data to support highly informed health care decisions. He has been involved in the assessment, treatment and investigation of various CNS disorders in both industry and academia for more than 20 years, was one of the original Worldwide team members beginning in 1998 and is a cofounder of the current Worldwide.
Dr. Riordan has been the primary author of numerous protocols in neurologic, psychiatric, and analgesic indications across all phases of development. He has been involved in several clinical development programs and has participated in numerous advisory boards and regulatory interactions. During his tenure as the Clinical Lead for Worldwide’s Early Phase Development Unit, he was responsible for helping to establish the Specialized Patient Study Unit. He also spent several years in the departments of neurology and psychiatry at Jefferson, the University of Pennsylvania, and Dartmouth medical schools.
Dr. Riordan holds a BA in psychology and biology from Bloomsburg University of Pennsylvania, an MA in experimental psychology: quantitative methods from University of Hartford, an MA in biopsychology from Stony Brook University, and a PhD in biopsychology, specialty in neuropsychology, from State University of New York at Stony Brook.